Abstract
Alzheimers disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid- beta (Aβ) peptides. According to the amyloid hypothesis, Aβ peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Aβ is a potential therapeutic for the treatment of humans with AD. While anti-Aβ immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.
Keywords: Immunotherapy, Microhemorrhages, Vascular Pathology, Transgenic Mice, Aβ peptides, amyloid hypothesis
CNS & Neurological Disorders - Drug Targets
Title: Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
Volume: 8 Issue: 1
Author(s): Donna M. Wilcock and Carol A. Colton
Affiliation:
Keywords: Immunotherapy, Microhemorrhages, Vascular Pathology, Transgenic Mice, Aβ peptides, amyloid hypothesis
Abstract: Alzheimers disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid- beta (Aβ) peptides. According to the amyloid hypothesis, Aβ peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Aβ is a potential therapeutic for the treatment of humans with AD. While anti-Aβ immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.
Export Options
About this article
Cite this article as:
Wilcock M. Donna and Colton A. Carol, Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice, CNS & Neurological Disorders - Drug Targets 2009; 8 (1) . https://dx.doi.org/10.2174/187152709787601858
DOI https://dx.doi.org/10.2174/187152709787601858 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
Current Pharmaceutical Design Prevention of Serum Albumin Glycation/Fibrillation by β-Cyclodextrin Functionalized Magnetic Nanoparticles
Protein & Peptide Letters Molecular Modeling of Brassicaceae Derivatives for Inhibiting Lipoxygenases: A Promising Therapeutic Strategy
Current Drug Discovery Technologies Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Structurally Unprecedented Metabolites from Marine Sponges
Current Organic Chemistry Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Editorial - Advances of Alzheimers Disease Research: Crossroad of Basic and Translational Studies
Current Alzheimer Research Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Thienyl Pyrimidine Derivatives with PrPSc Oligomer-Inducing Activity are a Promising Tool to Study Prions
Current Topics in Medicinal Chemistry Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery Synthesis and In vitro Evaluation of Thiadiazole Derivatives as AChE, Bu- ChE and LOX Inhibitors
Letters in Drug Design & Discovery CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Melatonin Decreases Levels of S100β and NFκB, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease
Current Aging Science Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy Editorial [Hot Topic: Role of Gene and Stem Cell Therapies in the Treatment of Neurological Disorders (Guest Editor: U. Galderisi)]
Current Drug Targets Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems
Current Neuropharmacology